KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Investing Activities (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Cash from Investing Activities data on record, last reported at -$25.4 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 132.38% year-over-year to -$25.4 million; the TTM value through Dec 2025 reached -$92.4 million, down 2336.44%, while the annual FY2025 figure was -$92.4 million, 2336.44% down from the prior year.
  • Cash from Investing Activities reached -$25.4 million in Q4 2025 per RIGL's latest filing, up from -$33.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $22.6 million in Q1 2022 and bottomed at -$49.7 million in Q2 2021.
  • Average Cash from Investing Activities over 5 years is -$5.0 million, with a median of $545000.0 recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 424.96% in 2024, then crashed 3471.25% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at $6.5 million in 2021, then soared by 186.65% to $18.6 million in 2022, then crashed by 136.96% to -$6.9 million in 2023, then tumbled by 58.77% to -$10.9 million in 2024, then tumbled by 132.38% to -$25.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$25.4 million in Q4 2025, -$33.2 million in Q3 2025, and -$23.3 million in Q2 2025.